Revisit Every OncLive On Air Episode From June 2025

In case you missed any, below is a recap of the episodes of OncLive On Air® that debuted in June 2025. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM

In this episode of OncLive On Air, Elizabeth Mittendorf, MD, PhD, MHCM, of the Brigham and Women’s Hospital, the Dana-Farber Brigham Cancer Center, the Dana-Farber Cancer Institute, and Harvard Medical School all in Boston, Massachusetts, discussed her priorities for advancing the field of oncology during her term as the 2026 president of ASCO. She highlighted her commitment to improving multidisciplinary cancer management and addressing global cancer care. She also explained the crucial role of mentorship and sponsorship, and how she hopes to support the next generation of oncology professionals during her presidency.

“Our work is evidence based and reflects the full scope of challenges in cancer care, and we are committed to addressing the needs of our patients—as well as the needs of our members who provide that care,” Mittendorf said.

Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM

In part 2 of our conversation with Elizabeth Mittendorf, MD, PhD, MHCM, she shared ASCO’s strategic plan to address the effects of research funding cuts, the important role of the National Institutes of Health in growing scientific innovation, and emphasized the need for collaborative structural reforms for maintaining high levels of oncology progress, particularly in underfunded areas.

“I want to make sure our members know that ASCO is aware of the challenges related to research funding, and that we have a strategic approach to our advocacy efforts,” Mittendorf emphasized.

Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD

In this episode, Jonathan W. Goldman, MD, of UCLA, discussed key data and future clinical implications of the phase 2 LUMINOSITY study (NCT03539536) of telisotuzumab vedotin-tllv (Emrelis) in patients with c-MET–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). He also highlighted the importance of c-MET as a therapeutic target in NSCLC, as well as the mechanism of action of the investigational antibody-drug conjugate telisotuzumab vedotin.

“The primary end point of LUMINOSITY was overall response rate [ORR] in the c-Met–high group, which was 34.6%; this is meaningfully superior [compared with] other approved agents in the second-line [setting],” Goldman reported. “In the c-MET–intermediate group, the ORR was 24.1%.”

T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD

In this episode, Paolo Tarantino, MD, of Dana-Farber Cancer Institute, noted highlights in HER2-positive breast cancer research that were presented at the 2025 ASCO Annual Meeting, including data from the phase 3 DESTINY-Breast09 trial (NCT04784715) of first-line fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta) vs induction taxane plus trastuzumab (Herceptin) and pertuzumab (THP) in patients with HER2-positive metastatic breast cancer, and the phase 3 PATINA trial (NCT02947685) of maintenance CDK4/6 inhibition in patients with hormone receptor (HR)–positive, HER2-positive disease.

“This was an impressive ASCO,” according to Tarantino. “Talking of HER2-positive breast cancer, there was 1 key study that challenged current standards of care [SOCs] after over a decade since the phase 3 CLEOPATRA trial [NCT00567190] NCT00567190] set the first-line standard in estrogen receptor–positive metastatic breast cancer, and this is DESTINY-Breast09.”

Revumenib Shows Promise Across Menin-Sensitive AML Subtypes and Could Shift Treatment Paradigms: With Naval Daver, MD

In this episode, Naval Daver, MD, of The University of Texas MD Anderson Cancer Center in Houston, highlighted data from the phase 1 AUGMENT-101 trial (NCT04065399) of revumenib in patients with relapsed/refractory NPM1-mutated acute myeloid leukemia (AML), the potential efficacy of menin inhibitors in NUP98-rearranged AML, and the different sensitivities of menin-targeted agents across molecular subtypes of AML.

“We showed in a pretty big population that there was no difference in terms of survival in [patients] with relapsed NPM1 mutation [who received second] salvage and [third] salvage [therapies], and the median survival is approximately 6 to 7 months,” Daver explained.

The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH

In this episode, Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute and Harvard Medical School, noted the evolution of androgen receptor (AR) inhibition for patients with metastatic hormone-sensitive prostate cancer, including the expanded FDA approval of darolutamide (Nubeqa) for this population; factors she considers when determining whether docetaxel plus darolutamide is the optimal treatment regimen for patients; and the importance of continuing to drive consensus regarding prostate cancer management practices.

“It’s important that we have had the advance where we can use AR pathway inhibitors in combination with androgen deprivation therapy (ADT) to improve disease control outcomes, prolonging the time until progression of disease and prolonging survival in the metastatic hormone-sensitive disease compared with ADT alone,” Morgans explained. “This advance has been important because it allows patients who may not necessarily be fit for more intensive treatment approaches to still have improvements in their outcomes.”

Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS

In this episode, Kate Gasparini, PharmD, BCOP, BCPPS, of Memorial Sloan Kettering Cancer Center in New York, New York, explained key aspects of her role as a pediatric oncology clinical pharmacy specialist, treatment administration challenges for patients with dysphagia, and how developing liquid formulations of common therapies can increase access to these medications and improve treatment adherence.

“Whether a medication is available as a liquid formulation may seem trivial, but for those of us who work every day with this patient population, we know it makes all the difference,” Gasparini emphasized. “It can improve the quality of life [QOL] for patients and their families to have a liquid formulation that’s easy to administer and readily available for a patient who has difficulty swallowing, especially for oral chemotherapy agents, which are essential in the treatment of certain pediatric [patients with] cancer. It’s one less thing for patients and families to worry about when they’re undergoing these intensive treatments and, as the treating team, we know the patient will be able to get the therapy safely and reliably. It’s an additional peace of mind.”

How Firsthand Breast Cancer Experience Shaped a Surgeon’s Mission to Educate Colleagues and Empower Patients: With D. Ross Camidge, MD, PhD; and Liz O’Riordan, FRCS, PhD

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, was joined by Liz O’Riordan, FRCS, PhD, a breast surgeon who has had breast cancer. O’Riordan shared how her breast surgery career intersected with her breast cancer diagnosis and treatment, the crucial role of survivorship communication between patients and health care providers, and O’Riordan’s own career transition from surgery to patient advocacy.

“I would like to be the go-to breast cancer person for experience and advice,” said O’Riordan. “It would be good to try and reach as many people as possible.”

“There is that mental barrier about being open with your patients,” Camidge noted. “It can work both ways.”

Conversations About BTK Inhibitors and CAR T-Cell Therapies Bridge Gaps in Leukemia and Lymphoma: With Alexey Danilov, MD, PhD

In this episode, Alexey Danilov, MD, PhD, of City of Hope in Duarte, California, noted developments and controversies surrounding the management of hematologic malignancies, chemotherapy-free regimens that are reshaping SOCs for patients with mantle cell lymphoma, the current and evolving role of BTK inhibitors for chronic lymphocytic leukemia, and the growing prevalence of CD19-directed CAR T-cell therapies for diffuse large B-cell lymphoma.

“[There are] guidelines published by different entities in all these respective fields, such as the National Comprehensive Cancer Network Guidelines; however, these guidelines mostly focus on treatment approaches [derived from] evidence that already exists, and [they] don’t necessarily discuss controversies that physicians face on a daily basis in their clinical practice,” Danilov said.

Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD

In this episode, Michael Dennis, MD, of Dana-Farber Cancer Institute and Harvard Medical School, explained the latest updates to the National Comprehensive Cancer Center guidelines for nasopharyngeal carcinoma, notable findings from the phase 3 JUPITER-02 trial (NCT03581786) of frontline toripalimab-tpzi (Loqtorzi) plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma, and what the future may hold for patients with locally advanced disease.

“Most places in the United States now are becoming familiar with [toripalimab] and have it as an option to offer to patients,” Dennis stated. “I choose gemcitabine, cisplatin, and toripalimab for patients in the first-line setting.”

ASCO 2025 Plenary: SERENA-6

In this episode, a collaboration between OncLive and Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis; and Karine Tawagi, MD, of the University of Illinois in Chicago, spotlighted key efficacy, safety, and patient-reported outcomes from the phase 3 SERENA-6 trial (NCT04964934), which investigated switching to camizestrant plus a CDK4/6 inhibitor compared with continuing a SOC aromatase inhibitor plus a CDK4/6 inhibitor in the frontline setting for patients with HR-positive, HER2-negative ESR1-mutated advanced breast cancer. They also explained how these data might be currently applicable to clinical practice and limitations of the trial to be aware of.

“Some of the strengths of the SERENA-6 trial are that it [was designed to detect] ESR1 mutations early before there was progression seen on scans,” Armstrong explained. “This was enabling a proactive switch. This is pioneering a new role for circulating tumor DNA testing, as well as for therapeutic management.”

“For fellows, time to second progression [PFS2] is defined as the time from randomization to progression on second-line therapy,” Tawagi noted. “The lack of crossover is concerning as far as the PFS2 benefit.”

T-DXd’s Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD

In this episode, Misako Nagasaka, MD, PhD, of the University of California Irvine School of Medicine, discussed current standards for the second-line management of HER2-mutated NSCLC, the evolving role of T-DXd in this setting, and the importance of using HER2 immunohistochemistry (IHC) testing in routine clinical practice.

“HER2 in NSCLC is an exciting field,” Nagasaka shared. “First-line treatment may shift with the readout of clinical trials exploring targeted therapies in the first-line setting.”

BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD

In this episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, of Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, of Allegheny Health Network in Pittsburgh, Pennsylvania, for part 2 of their conversation on colorectal cancer (CRC) management. They discussed treatment sequencing options for patients with BRAF V600E–mutant CRC, therapeutic considerations for patients with microsatellite instability–high/BRAF V600E–mutant tumors, and the importance of conducting molecular profiling early in the treatment course to increase options for personalized treatment selection.

“If a patient received FOLFOX [leucovorin, fluorouracil, and oxaliplatin] and unfortunately had a progression within the first 6 months to 1 year, I don’t tend to use FOLFOX again, because this patient has a tumor that has an aggressive biology and progressed on FOLFOX within early stages,” according to Malla. “That’s a patient population [in which I] would like to use a different chemotherapy backbone, like FOLFIRI [leucovorin, fluorouracil, and irinotecan].”

“On the left side, [there tends to be] more HER2[-positive] disease,” Park noted. “Let’s say we have a [patient with a] left-sided [tumor] and they progress on FOLFOX with cetuximab [Erbitux], maybe panitumumab [Vectibix], and then they have this HER2 3+ IHC [disease]. The general medical oncologists are thinking FOLFIRI with bevacizumab [Avastin], but now we have a T-DXd approval, and we have good data on HER2.”

IMA203 emerges as a Novel Investigational Agent in Cutaneous Melanoma: With Justin Moser, MD

In this episode, Justin Moser, MD, of HonorHealth Research Institute and the Arizona State University School of Medicine and Advanced Medical Engineering in Scottsdale, explained the mechanism of action of IMA203, phase 1 data with this treatment in patients with melanoma that prompted the launch of the phase 3 SUPRAME trial (NCT06743126), and the potential future implications of this ongoing research.

“IMA203 is a novel treatment for melanoma…. It’s the first engineered cell therapy that we have for the potential [management] of melanoma,” Moser said. “Many [standard melanoma therapies] have 10%, 20%, maybe up to 25% response rates in the refractory setting. [IMA203] looks like it has much higher potential for patients with refractory melanoma.”